These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2502062

  • 1. Immunoaffinity purification of factor VIII.
    Weinstein RE.
    Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE, Gomperts E, Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ.
    Thromb Haemost; 1992 Jan 23; 67(1):19-27. PubMed ID: 1615478
    [Abstract] [Full Text] [Related]

  • 5. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK, Lee JM, Byun TH, Park SY, Kim YH.
    Biotechnol Prog; 2001 Jan 23; 17(6):1119-27. PubMed ID: 11735450
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ, Lusher JM, Cohen AR, Salzman P.
    Semin Hematol; 1990 Apr 23; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [Abstract] [Full Text] [Related]

  • 9. Progress in large-scale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography.
    Mori F, Nardini I, Rossi P, Nardini C, Farina C.
    Vox Sang; 2008 Nov 23; 95(4):298-307. PubMed ID: 19138259
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.
    Lusher JM, Salzman PM.
    Semin Hematol; 1990 Apr 23; 27(2 Suppl 2):1-7. PubMed ID: 1965615
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
    Mannucci PM.
    Thromb Haemost; 1995 Jul 23; 74(1):437-9. PubMed ID: 8578501
    [Abstract] [Full Text] [Related]

  • 18. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS, Choi YW, Kang Y, Sung HM, Shin JS.
    J Microbiol Biotechnol; 2008 May 23; 18(5):997-1003. PubMed ID: 18633304
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.